Biomarkers in Brain Disease / Edition 1 available in Paperback
- Pub. Date:
Advances in biomarker development are revolutionizing the way westudy, diagnose and treat disease. However, progress in thedevelopment and use of biomarkers for diseases of the centralnervous system has been limited by a number of difficulties including the inherent barriers associated with studying the brain.Development of reliable biomarkers for brain disorders woulddramatically accelerate research on the etiology, pathophysiology,disease progression, and therapeutic development of many veryprevalent and devastating diseases including Alzheimer's disease,Parkinson's disease, multiple sclerosis, and others. Internationalexperts in the field have contributed chapters to this volume thatdiscuss the latest advances in biomarker technologies and biomarkerdevelopment for brain disorders, as well as the logistical,regulatory and funding challenges experienced by scientists workingon clinical trials for biomarkers
NOTE: Annals volumes are available for sale as individualbooks or as a journal. For information on institutional journalsubscriptions, please visit www.blackwellpublishing.com/nyas.
ACADEMY MEMBERS: Please contact the New York Academy ofSciences directly to place your order (www.nyas.org).Members of the New York Academy of Science receive full-text accessto the Annals online and discounts on print volumes. Please visithttp://www.nyas.org/MemberCenter/Join.aspxfor more information about becoming a member.
Table of ContentsPreface.
1. The Uses of Biomarkers in Drug Development (OrestHurko).
2. Biomarkers, Dementia, and Public Health (C.F. Wright, A.Hall A, F.E. Matthews, and C. Brayne).
3. Imaging Biomarkers in Alzheimer's Disease (Natalie Ryanand Nick C. Fox).
4. CSF Biomarkers: Pin-pointing Alzheimer pathogenesis(Niklas Mattsson, Kaj Blennow, and Henrik Zetterberg).
5. AddNeuroMed: The European Collaboration for the Discovery ofNovel Biomarkers for Alzheimer's Disease (Simon Lovestone, PaulFrancis, Iwona Kloszewska, Patrizia Mecocci, Andrew Simmons, HilkkaSoininen, Christian Spenger, Magda Tsolaki, Bruno Vellas, Lars-OlofWahlund, Malcolm Ward, on behalf of the AddNeuroMedconsortium).
6. MRI Measures of Alzheimer's Disease and the AddNeuroMed Study(Andrew Simmons, Eric Westman, Sebastian Muehlboeck, PatriziaMecocci, Bruno Vellas, Magda Tsolaki, Iwona Kloszewska, Lars-OlofWahlund, Hilkka Soininen, Simon Lovestone, Alan Evans, ChristianSpenger, for the AddNeuroMed consortium).
7. Identifying Early Markers of Alzheimer's disease usingQuantitative Multiplex Proteomic Immunoassay Panels (Holly D.Soares, Yu Chen, Marwin Sabbagh, Alex Rohrer, Elisabeth Schrijvers,and Monique Breteler).
8. Proteomics for Brain Disorders: The Promise for Biomarkers(Malcolm Ward, Andreas Güntert, James Campbell, and IanPi).
9. Use of Genetic Variation as Biomarkers for Alzheimer'sdisease (Christiane Reitz and Richard Mayeux).
10. Biomarkers in Huntington's and Parkinson's Disease(Gráinne C. O'Keeffe, Andrew W. Michell, Roger A.Barker).
11. Biomarkers in Oncology (Trials and Tribulations: SheilaE. Taube).
12. Biomarkers in Alzheimer's Disease: Not Yet SurrogateEndpoints (N. Coley, S. Andrieu, J. Delrieu, T. Voisin, and B.Vellas).